CAR-T Cell Therapy in China: 7 Questions Every International Patient Asks
CAR-T is not an ordinary surgery. This article answers the questions patients ask most, in plain language, focusing on what actually happens.
"My lymphoma has relapsed. My doctor at home says CAR-T may be the only option left. I've heard China offers it at a much lower cost — but I have no idea what actually happens once I get there."
This is the mindset of many overseas patients and their families. CAR-T is not an ordinary surgery. It involves cell collection, genetic engineering, a waiting period, infusion, and close monitoring — spanning several weeks. This article answers the questions patients ask most, in plain language, focusing on what actually happens.
1. Am I eligible for CAR-T?
The CD19-targeted CAR-T products currently approved in China are primarily indicated for adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL NOS), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL transformed from follicular lymphoma.
In plain terms: CAR-T is considered when standard chemotherapy regimens have been tried two or more times and the disease has progressed or relapsed.
China also has BCMA-targeted CAR-T products for relapsed/refractory multiple myeloma, and in 2026 approved the world's first Claudin18.2-targeted CAR-T for Claudin18.2-positive gastric cancer — the only approved solid-tumor CAR-T globally. If your cancer type falls outside these indications, you would need to check whether a suitable clinical trial or alternative therapy is available.
Eligibility is not something patients determine from online research. It is assessed by the hematology team at a CAR-T-certified center based on pathology reports, treatment history, imaging, and overall fitness. After submitting medical records remotely, a written eligibility opinion is typically provided within 1–2 weeks.
2. How long does the whole process take?
The treatment journey can be broken down into seven phases:
| Phase | Location | Approximate Duration |
|---|---|---|
| ① Records review & eligibility screening | Remote (from home) | 1–2 weeks |
| ② Visa, travel & baseline assessment | China | A few days |
| ③ T-cell collection (leukapheresis) | China | One session, 3–4 hours |
| ④ Cell manufacturing & genetic engineering | GMP laboratory | 2–3 weeks |
| ⑤ Lymphodepleting conditioning chemotherapy | China | 3 days |
| ⑥ CAR-T cell infusion | China | ~30 minutes |
| ⑦ Inpatient monitoring & near-centre stay | China | ≥10–14 days inpatient, then near the centre until ~4 weeks post-infusion |
Plan for approximately 7–9 weeks in China.One companion is strongly recommended — not only for emotional support, but because someone needs to monitor the patient's condition around the clock during the first two weeks after infusion.
Note: CAR-T treatment requires a formal medical visa; the 30-day visa-free entry is not sufficient given the length of stay. The hospital issues a visa invitation letter, and the coordinating team assists with the application process.
3. What do collection and infusion feel like?
Collection (leukapheresis): Similar to an extended blood donation. Blood is drawn from one arm, a machine separates out the T-cells, and the remaining blood returns through the other arm. You remain awake throughout the 3–4 hour procedure and can lie down, use your phone, or listen to music. The collected T-cells are then couriered under cold-chain conditions to a GMP laboratory for genetic engineering.
The 2–3 week manufacturing wait: This is the "nothing to do but wait" phase. Patients can engage in light activity, with the medical team advising on appropriate exertion levels. Coordinators typically arrange long-stay accommodation near the hospital.
Lymphodepleting conditioning: Three days before infusion, patients receive a chemotherapy regimen of fludarabine combined with cyclophosphamide. The purpose is to clear existing lymphocytes from the body, creating space for CAR-T cells to expand. This conditioning is generally milder than conventional cancer chemotherapy, though nausea and fatigue may still occur.
Infusion: The pivotal moment of the entire journey is, deliberately, unremarkable — a bag of milky-white cell suspension administered through an IV line over approximately 30 minutes. No scalpel, no general anaesthesia.
4. How serious are the side effects?
This is the question every patient fears. To be straightforward: CAR-T does have defined, potentially severe side effects, but they are predictable and manageable, and they only occur at certified centres equipped with emergency response capabilities.
The two most common:
• Cytokine release syndrome (CRS): As CAR-T cells activate and expand after infusion, they may cause fever, low blood pressure, and rapid heart rate. Most cases are mild to moderate and can be controlled with tocilizumab (an IL-6 receptor antagonist). Severe cases may require vasopressor support and ICU monitoring. The key is early recognition and prompt management.
• Immune effector cell-associated neurotoxicity syndrome (ICANS): May present as confusion, language difficulty, or impaired writing — usually temporary. Clinical staff perform daily neurological assessments (for example, asking patients to write a sentence or identify objects).
Other effects include low blood cell counts, infection risk, and fatigue.
This is why patients must remain hospitalized for at least 10–14 days after infusion, and stay within reach of the centre for approximately four weeks thereafter — the highest-risk window for side effects is the first two weeks. Any fever (≥38°C / 100.4°F) or feeling unwell must be reported immediately, not the next morning.
5. What does CAR-T cost in China?
This is the most practical question. China's CAR-T market is undergoing significant price changes in 2026:
• Cell product alone: Traditional commercial CAR-T products are priced in the range of RMB 990,000–1,290,000 (approximately USD 140,000–180,000). Domestic products with fully localized supply chains have brought prices down to approximately RMB 230,000–400,000 (USD 32,000–56,000) in 2026. Five CAR-T products have been included in the National Commercial Health Insurance Innovative Drug Catalogue, and some city-level supplementary insurance plans (Huimin Bao) provide partial reimbursement for Chinese residents.
• All-inclusive treatment package (covering the cell product, apheresis, conditioning chemotherapy, infusion, approximately 3–4 weeks of inpatient monitoring, nursing, interpreter support, and airport transfers): depending on the hospital and product combination, international patients can expect a total package cost in the range of USD 110,000–210,000.
For comparison, the list price of the CAR-T drug alone in the United States is typically USD 500,000–700,000+, with total treatment costs reaching USD 650,000–900,000. Treatment in China costs approximately 20%–30% of the US total.
It is important to note that complication management, extended stays beyond the defined package, and therapies unrelated to CAR-T are generally not included in the base package. Reputable institutions provide a separate written quotation before such costs are incurred. International patients typically pay out of pocket; some premium international health insurance plans may provide partial coverage, which should be confirmed with the insurer in advance.
6. What happens after returning home?
Before discharge, the hospital provides a bilingual (Chinese–English) discharge package containing:
• Treatment summary and infusion details
• Complication log and medication record
• Blood count trends and CAR-T cell expansion data
• Follow-up schedule (weekly reviews in the first month, every two weeks in months 2–3, with intervals gradually extended thereafter)
• A handover note for the patient's home haematologist
It is advisable to involve the home treating physician before departure, ensuring a seamless transition of care after return. Response assessment is typically conducted via PET-CT at 1–3 months post-infusion, with imaging subsequently available for remote review by the Chinese team.
Most patients see a clear treatment response within 1–3 months after infusion. According to Chinese registrational clinical data, CD19 CAR-T for r/r LBCL achieves an objective response rate of approximately 80%, with a complete response rate of approximately 50%–70% (varying by product), and some patients achieve long-term disease-free survival.
7. Practical checklist before departure
CAR-T is not a cure-all, but for patients with blood cancers who have exhausted multiple rounds of chemotherapy and have few options remaining, it may be the closest thing to a cure currently available. China's accessibility in this field — the number of approved products, treatment centres, and cost levels — is improving rapidly, which is why a growing number of international patients are turning their attention to China.
If you are considering this path, the most important advice is: submit your medical records for professional assessment first, obtain a clear written opinion on whether CAR-T is appropriate for you, and only then decide whether to travel. Do not rely solely on online information, and do not book a flight without an eligibility assessment.
Professional medical coordination services can assist with medical record organization and translation, hospital liaison, visa invitation letters, accommodation arrangements, and full-time interpretation and clinic accompaniment. However, the final decision on treatment always rests with you and your physician.
